Page 9 - Bharat Biotech

Covaxin's final product has no calf serum, Bharat Biotech and govt clarify

Health ministry says this has been used for decades in Polio, Rabies, and Influenza vaccines, is neither used in growth of SARS CoV2 virus nor in the final formulation

Sustainable pricing

Govt and vaccine makers should be transparent

Calf serum used in manufacturing of viral vaccines: Bharat Biotech

However, the final formulation of its Covid-19 vaccine Covaxin is free from all impurities, the firm said

Ocugen selects Jubilant HollisterStier as manufacturer for Covaxin in US

Bharat Biotech's US and Canada partner for Covaxin, said it has chosen Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for the vaccine for the North American countries

Covid-19 vaccine Covaxin at Rs 150 not sustainable: Bharat Biotech

Higher price in private market required to offset part of the costs, argues firm

Bharat Biotech says higher pricing of Covaxin required in private markets

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said

India Coronavirus Dispatch: Lowest daily jump in cases since March 31

New Covid strain on world radar stems from Delta variant, Covaxin is world's third costliest jab and more-news relevant to India's fight against the pandemic

Covid: Committed to data transparency on Covaxin, says Bharat Biotech

Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent, and the company has so far published nine research studies on its safety and efficacy. "Covaxin's scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers -scientists,9 studys & data published," BharatBiotech CoFounder & Joint MD Suchitra Ella said in a tweet. The complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India, Bharat Biotech said in a statement. "In a timely approach to peer review, the company has already published as many as nine research studies on the safety and efficacy of Covaxin in five globally reputed peer-reviewed journals in a span of just twelve months," it added. Covaxin, a whole-virion inactivated coronavirus vaccine, is the first and only product to have published any data from ...

Covid-19 pandemic: Bharat Biotech's Covaxin set for clinical trials in US

FDA asks Bharat Bio's US partner Ocugen to apply for full authorisation

Bharat Biotech to conduct additional clinical trials for USFDA nod

Timelines will be delayed; firm has received EUSs from 14 other countries

FDA denies Bharat Bio's US partner emergency approval for Covaxin vaccine

US FDA has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application route with additional data, nixinghopes of Emergency Use Authorisation

Top Headlines: Pfizer Covid vax's 'India price', Twitter India seeks a week

Business Standard brings top headlines on Thursday

Covaxin Phase-3 efficacy analysis to be made public by July: Bharat Biotech

The company is also doing phase-4 trials for real world effectiveness of the jab

Bharat Biotech expects peer review of Covaxin's Phase 3 trials data in Q4

Bharat Biotech is yet to publish the data of Covaxin's phase-3 trial

Centre fixes maximum price for Covid-19 vaccines at private hospitals

The CoWIN system would also ensure that the prices declared by various private vaccination centres do not exceed the maximum price

Covid-19 vaccination: Govt books 440 million doses with 30% advance

250 mn Covishield and 190 mn Covaxin doses meant for Aug-Dec period

Study on Covishield, Covaxin antibody response is limited: Bharat Biotech

Raches Ella, project lead, Covid-19 vaccines at the firm says he is surprised that media and researchers are drawing conclusions based on non-peer reviewed work

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

Free Covid-19 vaccine for all above 18 years from June 21: PM Modi

Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.